Introduction
The integrity and functional activity of the endothelial monolayer play a crucial role in the prevention of atherosclerosis in hypertension. Recent findings suggest that the injured endothelial monolayer is regenerated by circulating bone marrow (BM)-derived endothelial progenitor cells (BM-EPCs), which accelerates re-endothelialization and limits atherosclerotic lesion formation ( 1 -4 ) . This beneficial property of BMEPCs makes them attractive for cell therapy targeting the regeneration of ischemic tissue. Since BM-EPCs may contribute to postnatal neovascularization, an improved understanding of the regulation of EPC kinetics may provide new insights into the pathogenesis of vasculogenesis. On the other hand, various risk factors for coronary artery disease (CAD), such as diabetes, hyperlipidemia, hypertension, and smoking, affect the number and functional activity of EPCs in healthy volunteers ( 5 ) and in patients with CAD ( 6 ) . By multivariate analysis of various risk factors, hypertension has been identified as a major independent predictor for impaired EPC migration ( 6 ) . In addition, Min et al . have demonstrated that angiotensin-converting enzyme inhibitor therapy with ramipril augmented circulating EPCs with enhanced functional activity in patients with stable CAD ( 7 ) . Given the important role of EPCs for neovascularization of ischemic tissue, a decrease in the number and activity of EPCs could contribute to an insufficient regeneration of the endothelium, which could lead to endothelial dysfunction.
In our recent culture study, we showed that Ang II increases the rate of senescence of EPCs, and that this appears to be a consequence of its ability to stimulate gp91phox expression and thus superoxide formation ( 8 ) . We have also demonstrated that the ability of Ang II to induce senescence involves the suppression of telomerase, which is known to be a key player in the determination of cell life span ( 8 ) . However, it remains unclear whether Ang II affects the differentiation and senescence of BM-EPCs in vivo . Therefore, in the present study, we investigated the influence of Ang II on the differentiation and senescence of BM-EPCs in an Ang II-infusion rat model.
Methods
The Ethics Committee for Animal Experiments at the Wakayama Medical University approved the experimental protocol used in this study. The experiment was performed according to the Guidelines for Animal Experimentation at the Wakayama Medical University.
Animals and Protocol
Thirty-two male Wistar rats aged 10 weeks were housed in a room under constant-temperature and a 12-h light/12-h dark cycle. The rats were infused subcutaneously by mini-osmotic pumps (model 2002; Alza Corporation, Mountain View, USA) with Ang II (0.084 mg/kg/day) or vehicle either alone or in combination with an Ang II type 1 receptor (AT1R) blocker (valsartan; 0.3 mg/kg/day) or hydralazine (10 mg/kg/ day). Valsartan was supplied by Novartis Pharmaceutical Company (Basel, Switzerland). These treatments were performed for 2 weeks before preparation. Blood pressure and heart rate were measured at 2 weeks before and after preparation. Systolic blood pressure (SBP) was measured by tail-cuff plethysmography according to the procedure described by Bunag et al. (9) .
Isolation of Mononuclear Cells and Cell Culture
BM cells were obtained from the tibias and femurs of 12-week-old male Wistar rats. BM-derived mononuclear cells (BM-MNCs) were isolated by density gradient centrifugation with Histopaque 1083 (Sigma Chemical Co., St. Louis, USA). After purification with 3 washing steps, 10 × 10 6 BMMNCs were plated on vitronectin-coated 6-well plates. Cells were cultured in endothelial basal medium-2 (EBM-2) (Clonetics, Walkersville, USA) with supplements (3 μg/ml bovine brain extract, 30 μg/ml gentamycin, 50 μg/ml amphotericin B, 10 μg/ml human epidermal growth factor, and 5% fetal bovine serum [FBS] ). In addition, peripheral blood mononuclear cells (PB-MNCs) were isolated from male Wistar rats treated with Ang II or vehicle either alone or in combination with valsartan at two time points as described above.
Telomeric Repeat Amplification Protocol Assay
For quantitative analyses of telomerase activity, a telomeric repeat amplification protocol (TRAP) assay, in which the telomerase reaction product is amplified by polymerase chain reaction (PCR), was performed using a TeloTAGGG PCR ELISA PLUS kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's protocol as previously described (8, 10) .
Proliferative Activity Assay
Mitogenic activity was assayed using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96 AQ; Promega, Madison, USA). BM-endothelial cell (EC)-like cells were harvested 7 days after culture and re-seeded with a 96-well plate (1 × 10 4 cells) in 0.1 ml of EBM-2 medium supplemented with 0.5% bovine serum albumin (BSA) in the presence of human recombinant vascular endothelial growth factor (VEGF) (100 ng/ml; R&D Systems, Minneapolis, USA) overnight. After 24 h in culture, MTS/phenazine methosulfate (PMS) solution was added to each well for 3 h, at which time the light absorbance at 490 nm was detected using an ELISA plate reader (Bionetics Laboratory, Kensington, USA). (Table 1) . BM-EPCs were characterized as adherent cells that were double-positive for both lectin and DiLDL uptake. The number of differentiated, adherent BM-EPCs in the Ang II treatment group was significantly lower than that in controls (Fig.  1) . Addition of valsartan significantly reversed this effect (Fig. 1) . On the other hand, hydralazine had no effect on BMEPCs.
The rate of senescence, as assessed by acidic β-galactosidase staining, was significantly higher in BM-EPCs in the Ang II treatment group than in controls or the Ang II + hydralazine treatment group (Fig. 2) . On the other hand, Ang II-induced senescence of BM-EPCs was significantly inhibited by concomitant administration of valsartan (Fig. 2) . Cellular senescence is critically influenced by telomerase, which elongates telomeres, thereby counteracting the telomere length reduction induced by cell division. Therefore, we measured telomerase activity by a TeloTAGGG telomerase PCR ELISA. As demonstrated in Fig. 3 , telomerase activity in BMEPCs was significantly lower in rats treated with Ang II alone than in the Ang II + valsartan treatment or control groups.
Having demonstrated that Ang II accelerated the onset of senescence, we next examined whether this effect translates into a decrease in proliferation. An MTS assay demonstrated that the mitogenic activity in BM-EPCs of the Ang II treatment group was significantly lower than that in the untreated control group, and this effect was significantly reversed by valsartan (Fig. 4) .
Finally, we investigated the effect of Ang II on the number of PB-EPCs. As shown in Fig. 5 , Ang II significantly decreased the number of PB-EPCs. In fact, the number of PBEPCs at 1 and 2 weeks after the Ang II treatment was significantly decreased compared with that in the control group, and this effect was significantly inhibited by the co-treatment with valsartan. 
Discussion
The functional regeneration of ischemic tissue by improved neovascularization and subsequent tissue repair is critically dependent on the mobilization and integration of EPCs into the ischemic tissue. Moreover, infusions of EPCs expanded ex vivo can limit scar extension in the ischemic myocardium (11) and improve the recovery of contractility, and thus may be useful as a novel therapeutic approach (12) . However, it is conceivable that unfavorable clinical situations might be associated with dysfunctional BM-EPCs, defective vasculogenesis, and thus, impaired neovascularization. Indeed, Tepper et al. (13) reported that the proliferation and tube formation of EPCs were impaired in patients with type 2 diabetes compared with normal subjects. In the present study, we have shown that the differentiation of BM-EPCs derived from Ang II-infused rats at 12 weeks of age was significantly lower than that of BM-EPCs from untreated rats. Secondly, the Ang II-infused rats showed a significantly greater number of senescent BM-EPCs than the untreated rats. These effects were thought to be mediated via AT1R. Thirdly, Ang II significantly decreased the functional activity of BM-EPCs. Finally, the Ang II group had a significantly smaller number of PB-EPCs than the untreated rats. These results suggest that an AT1R blocker might have potential for the treatment of postnatal vasculogenesis of ischemic tissue. Repair of the vessel wall and generation of new blood vessels requires BM-derived stem cells or EPCs. In diseases of the vessel wall, such as atherosclerosis, the number of EPCs is reduced by 40% and their function is impaired (6) . By multivariate analysis of various risk factors, hypertension has been identified as a major independent predictor for impaired EPC migration. Unlike pluripotent stem cells, which are self renewing, EPCs have a defined life-span and, when they reach the Hayflick limit of telomere shortening that accompanies each mitotic event, they undergo replicative senescence. We have recently demonstrated in a culture study that shortterm exposure to Ang II potentiates VEGF-induced proliferation through the up-regulation of VEGF receptor kinase domain-containing receptor (KDR) (14) , while long-term exposure to Ang II inhibits this proliferation by inactivating telomerase and thereby accelerating the onset of EPC senescence. In the present study, infusion of Ang II for 14 days, like long-term exposure of Ang II in vitro, led to the acceleration of BM-EPC proliferation. Since antioxidant and statin treatment, by impeding reactive oxygen species (ROS) production, can delay senescence, and angiotensin-converting enzyme (ACE) inhibitor (ramipril) treatment increases the number and function of EPCs (7), the stimulation of senescence by Ang II in vivo as well as in vitro might involve its ability to generate ROS as well as its telomerase suppression. However, further studies will be needed to confirm our findings.
In conclusion, the results of the present study demonstrated that Ang II accelerated the onset of senescence in an Ang IIinfusion rat model, and that this effect may have been related to telomerase inactivation. Importantly, the inhibition of BM-EPC senescence by an AT1R blocker may improve the functional activity of BM-EPCs for potential cell therapy.
